|

Famitinib Clinical Trials

6 actively recruiting trials

Also known as: SHR-1020

Pipeline

Phase 2: 5Phase 3: 1

Top Sponsors

  • Fudan University5
  • Qian Chu1

Indications

  • Breast Cancer5
  • Cancer5
  • HER2-negative Breast Cancer4
  • Hormone Receptor Positive Tumor2
  • Triple Negative Breast Cancer (TNBC)2

Other6 trials

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
Phase 2
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.